Suggestions
Nicholas Restifo, MD
Cancer Immunotherapy Explorer and Entrepreneur
Nicholas Restifo, MD is a prominent figure in the field of cancer immunotherapy with an extensive background in research and development. He currently serves as the Chief Scientist and Head of R&D at Marble Therapeutics, a company based in Boston, Massachusetts.3
Career Highlights
Dr. Restifo has been pioneering new cell-based immunotherapies since 1989, including work on TIL (tumor-infiltrating lymphocytes), TCR-gene modified T cells, CAR-T cells, checkpoint blockade, and mechanisms of lymphodepletion.1 His career spans several decades and includes significant positions:
- Marble Therapeutics: Co-founder and Chief Scientist45
- National Institutes of Health: Principal Investigator for 30 years (July 1989 - July 2019)1
- Lyell Immunopharma: Executive Vice President of Research (July 2019 - February 2022)1
- RestifoPartners, LLC: Founder and CEO (February 2022 - Present)1
Education and Early Career
- Bachelor's degree in Natural Sciences from Johns Hopkins University (1979-1983)1
- Doctor of Medicine (MD) from New York University School of Medicine (1983-1987)1
- Postdoctoral Fellowship at Memorial Sloan Kettering Cancer Center (July 1988 - June 1989)1
Research Focus
Dr. Restifo is known as a "Cancer Immunotherapy Explorer".1 His work has been instrumental in advancing T cell-based immunotherapy, which has become a crucial area in cancer treatment.2 He has been involved in developing various innovative approaches to cancer immunotherapy throughout his career.
Current Work
At Marble Therapeutics, Dr. Restifo is likely applying his extensive experience in cancer immunotherapy to develop new cell-based treatments. His recent activities suggest a continued focus on advancing therapies for various cancers, including lung cancer.6
Highlights
Revealing the Secrets of Salt: Amplifying T Cell Assault on Tumors
We all love a little salt, but it turns out that this ubiquitous substance has profound effects on T cells. We showed a few years ago that elevated levels of potassium chloride – KCl, the bitter tasting cousin of sea salt, NaCl – had profound effects on T cell metabolism, including mitochondrial function, epigenetics and antitumor function (Vodnala, et al, Science, 2019). Our findings using elevated levels of KCl in T cell cultures to enhance their ‘stemness’ have been reproduced by many. It's exciting that the use of elevated levels of potassium chloride will soon be tested in clinical studies to enhance the power of adoptive cell transfer (ACT)-based T cell immunotherapy for cancer.
I was delighted to see two papers published last week in Nature Immunology that address the impact of NaCl on T cells. It turns out that while sodium and potassium may both affect the functions of Na+/K+-ATPase, they have effects on T cells that are in many ways opposite of each other.
This is especially clear in the paper from Soll … and Christina Zielinski. While KCl limits the acquisition of cytotoxic effector function, NaCl enhances CD8+ T cell effector functions. High NaCl levels induce a metabolic burst in CD8+ T cells, enhancing their cytotoxicity – an exciting development given the typically immunosuppressive tumor environment.
The paper from Caterina Scirgolea and Enrico Lugli also points out enhanced effector differentiation, albeit with some retention of stem-like transcripts including FOXO1, SATB1, and ID3.
The authors point out, wisely I think, that liberation of T cells into full blown effector function may come at the expense of stemness, thus limiting long-term maintenance of memory cells. But like checkpoint inhibition, which also enhances acquisition of effector function, cancer patients might well benefit from increased anti-tumor cytotoxicity.
Thus these two forms of salt might have their rightful place in the treatment of cancer patients with T cells – potassium chloride during expansion to preserve stemness and sodium chloride upon T cell transfer to enhance cytotoxicity.
Leveraging the simple ingredients like the amount and type of salt in a T cell culture might offer new therapeutic strategies in cell-based cancer treatment.
Fighting cancer is tough, it's sometimes likened to a wound that won't heal. Maybe rubbing some salt in this wound is just what it will take.
#Immunotherapy #CancerResearch #TCellTherapy #SodiumModulation #InnovationInScience #Oncology #TCellCytotoxicity #Biotech #ACT thanks to DALL-E for the nice image!
How LMO4 Advances T Cell Therapies Against Solid Tumors
Our research has long focused on addressing the challenge of understanding what drives stem-like memory T cells. These cells are exceedingly potent in driving T cell expansion, persistence, and function in anti-viral and anti-tumor immune responses.
Starting well over a decade ago, Luca Gattinoni, who was then a Staff Scientist in my lab, started looking into a seemingly odd transcriptional regulator named LMO4 (aka LIM domain only 4). If “LIM” sounds odd, it is merely an abbreviation for the first three proteins where the domain was found (Lin-11, Isl1, and Mec-3).
Luca noticed that LMO4 was upregulated when we treated T cells with a WNT agonist called TWS119, which we found in 2009 to be a potent potentiator of stem-like qualities in CD8+ T cells. Stem-like T cells are fundamental in both mouse and human T cell immunity, it seemed critical to understand the factors that underlie their superior functionality.
LMO4 is critical during development, but it is not highly expressed in T cells, and it’s not typically considered to be dynamically regulated in T cells. Thus, it didn’t seem to fit the pattern of so many of the other genes that we had been exploring in the stemness phenotype, like TCF7, LEF1, FOXO1, BACH2, and ID3 – all of which are expressed and regulated in the physiological setting.
LMO4 turned up again in a CRISPR activation (CRISPRa) gain-of-function screen as a key transcriptional regulator with the potential to enhance the stem-like qualities of CD8+ T cells. LMO4 has been implicated in various cancers, particularly breast cancer, where its overexpression is associated with tumor progression and poor prognosis. In cancer, LMO4 can promote cell proliferation, inhibit apoptosis, and contribute to metastasis, so perhaps it's not surprising that LMO4 would contribute to stemness in T cells.
I must hasten that I had virtually nothing to contribute to this talented multi-institutional team other than the very early work on the gene profiles related to WNT. But in my view, Roland C. Schelker, Jessica Fioravanti, DVM, PhD, Warren L., Luca Gattinoni and their teams demonstrate conclusively that LMO4 can indeed be repurposed to modulate cytokine signaling, particularly the IL-21-STAT3 pathway, which is essential for the generation of memory T cells while preventing terminal differentiation.
The authors leverage this biology to enhance tumor clearance and prolonged survival in preclinical models. These findings suggest that LMO4 manipulation could be a powerful strategy in the development of more effective T cell therapies for solid tumors.
This research opens new avenues for the application of synthetic biology in cancer immunotherapy, with the potential to significantly improve outcomes for patients with solid tumors.
https://lnkd.in/eG6BZww2
#CancerResearch #Immunotherapy #SyntheticBiology #CRISPR #TCells #OncologyInnovation
